MiNK Therapeutics, Inc. (INKT) Tops Q2 EPS by 3c

MiNK Therapeutics, Inc. (NASDAQ: INKT) reported Q2 EPS of ($0.07), $0.03 better than the analyst estimate of ($0.10).

For earnings history and earnings-related data on MiNK Therapeutics, Inc. (INKT) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Hafnia Limited (HAFN) Tops Q2 EPS by 1c
• FDA approves Takeda's rusfertide for polycythemia vera treatment